Apexigen

日期: 2018-08-21
浏览次数: 0

Apexigen is a clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. The company's pipeline of immuno-oncology therapeutic candidates is led by the APX005M program, which is currently in clinical development.Apexigen'sAPXiMAB™ technology platform enables Apexigen and its partners to discover high-quality antibody drug candidates against challenging disease targets. Apexigen has established eight corporate partnerships: five of these partners are conducting clinical trials of antibodies discovered using the APXiMAB™ platform.


Address: 505 China Resources Building, 2666 Keyuan South Road, Nanshan District, Shenzhen
TEL:0755-8831-6141
E-mail:info@efungcapital.com
Copyright ©2018 - 2021 Shenzhen Efung Investment Management Co. Ltd.
Rhino Cloud provides enterprise cloud services
犀牛云提供云计算服务